Maria Ceprián1, Laura Jiménez-Sánchez2, Carlos Vargas2, Lorena Barata2, Will Hind3, Jose Martínez-Orgado4. 1. Department of Biochemistry and Molecular Biology III, CIBERNED, IRICYS, School of Medicine, Universidad Complutense de Madrid, Spain; Instituto de Investigación Puerta de Hierro Majadahonda, Madrid, Spain. 2. Instituto de Investigación Puerta de Hierro Majadahonda, Madrid, Spain. 3. GW Research Ltd, Cambridge, UK. 4. Instituto de Investigación Puerta de Hierro Majadahonda, Madrid, Spain; Department of Neonatology, Hospital Clínico San Carlos - Instituto de Investigación Sanitaria San Carlos, Madrid, Spain. Electronic address: jose.martinezo@salud.madrid.org.
Abstract
BACKGROUND: and purpose: Currently there is no effective treatment for neonatal arterial ischemic stroke (AIS). Cannabidiol (CBD) is neuroprotective in models of newborn hypoxic-ischemic brain damage and adult stroke. The purpose of this work was to study the protective effect of CBD in a neonatal rat model of AIS. METHODS: Middle Cerebral Artery Occlusion (MCAO) was achieved in neonatal Wistar rats by introducing a nylon filament to the left MCA for 3 h; 15 min after removing the occluder vehicle (MCAO-V) or CBD single dose 5 mg/kg (MCAO-C) were administered i. p. Similarly manipulated but non-occluded rats served as controls (SHM). A set of behavioral tests was then conducted one week (P15) or one month (P38) after MCAO. Brain damage was then assessed by magnetic resonance imaging (MRI), proton magnetic resonance spectroscopy (H+-MRS) and histologic (TUNEL for cell death, immunohistochemistry for neuron, astrocyte and microglia identification) studies. RESULTS: CBD administration improved neurobehavioral function regarding strength, hemiparesis, coordination and sensorimotor performance as assessed at P15 and P38. MRI indicated that CBD did not reduce the volume of infarct but reduced the volume of perilesional gliosis. H+-MRS indicated that CBD reduced metabolic derangement and excitotoxicty, and protected astrocyte function. Histologic studies indicated that CBD reduced neuronal loss and apoptosis, and modulated astrogliosis and microglial proliferation and activation. CONCLUSIONS: CBD administration after MCAO led to long-term functional recovery, reducing neuronal loss and astrogliosis, and modulating apoptosis, metabolic derangement, excitotoxicity and neuro-inflammation.
BACKGROUND: and purpose: Currently there is no effective treatment for neonatal arterial ischemic stroke (AIS). Cannabidiol (CBD) is neuroprotective in models of newborn hypoxic-ischemic brain damage and adult stroke. The purpose of this work was to study the protective effect of CBD in a neonatal rat model of AIS. METHODS:Middle Cerebral Artery Occlusion (MCAO) was achieved in neonatal Wistar rats by introducing a nylon filament to the left MCA for 3 h; 15 min after removing the occluder vehicle (MCAO-V) or CBD single dose 5 mg/kg (MCAO-C) were administered i. p. Similarly manipulated but non-occluded rats served as controls (SHM). A set of behavioral tests was then conducted one week (P15) or one month (P38) after MCAO. Brain damage was then assessed by magnetic resonance imaging (MRI), proton magnetic resonance spectroscopy (H+-MRS) and histologic (TUNEL for cell death, immunohistochemistry for neuron, astrocyte and microglia identification) studies. RESULTS:CBD administration improved neurobehavioral function regarding strength, hemiparesis, coordination and sensorimotor performance as assessed at P15 and P38. MRI indicated that CBD did not reduce the volume of infarct but reduced the volume of perilesional gliosis. H+-MRS indicated that CBD reduced metabolic derangement and excitotoxicty, and protected astrocyte function. Histologic studies indicated that CBD reduced neuronal loss and apoptosis, and modulated astrogliosis and microglial proliferation and activation. CONCLUSIONS:CBD administration after MCAO led to long-term functional recovery, reducing neuronal loss and astrogliosis, and modulating apoptosis, metabolic derangement, excitotoxicity and neuro-inflammation.
Authors: Francisco Espejo-Porras; Laura García-Toscano; Carmen Rodríguez-Cueto; Irene Santos-García; Eva de Lago; Javier Fernandez-Ruiz Journal: Br J Pharmacol Date: 2018-05-06 Impact factor: 8.739
Authors: Aarón Del Pozo; María Villa; Carlos Vargas; David Castejón; M Encarnación Fernández-Valle; Ana Gutiérrez-Rodríguez; José Martínez-Orgado Journal: Pediatr Res Date: 2022-04-15 Impact factor: 3.756